resTORbio Email Format

Biotechnology ResearchMassachusetts, United States11-50 Employees

resTORbio is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing therapies for aging-related diseases. Its work addresses immunosenescence, the age-associated decline in immune function that increases susceptibility to infections in older adults, with RTB101 as the lead program, an oral TORC1 inhibitor evaluated alone and in combination with other mTOR inhibitors to bolster immune function and reduce respiratory tract infections. 

The company operates within the biotechnology research sector and centers its development on the mTOR pathway, specifically TORC1, to address aging-related health risks. In 2020, resTORbio merged with Adicet Bio, and Adicet Bio completed its acquisition of resTORbio later that year.

Sign up for free to view info

Company overview Employee directory